Enzymotec Ltd. Calls an Extraordinary General Meeting of Shareholders
March 10 2017 - 8:30AM
Enzymotec Ltd. (NASDAQ:ENZY) (the “Company”), today announced that
it will hold an Extraordinary General Meeting of Shareholders (the
“Meeting”) at 10:00 am local time on Tuesday, April 25, 2017 at the
Company’s offices, at Sagi 2000 Industrial Area, Migdal Ha’Emeq
2310001, Israel. The record date for shareholders entitled to vote
at the Meeting is Thursday, March 16, 2017.
The Meeting is being called for the following
purpose:
To approve the compensation of Mr. Erez Israeli,
the Company’s newly appointed President and Chief Executive Officer
and, in connection therewith, approve a one-time increase in the
number of ordinary shares available for grant under the Company’s
2013 Omnibus Equity Incentive Plan.
The Board of Directors unanimously recommends that
shareholders vote FOR the above proposal, which will be described
in a proxy statement to be made available to the Company’s
shareholders.
The shareholders may also act upon such other
matters as may properly come before the Meeting or any adjournment
or postponement thereof.
Approval of the above proposal requires the
affirmative vote of the holders of a majority of the voting power
represented at the Meeting in person or by proxy and voting on the
proposal. In addition to the foregoing simple majority requirement,
under the Israeli Companies Law 5759-1999 (the “Israeli
Companies Law”), the approval of the compensation of the
Company’s new President and Chief Executive Officer under the
proposal also requires that either:
- the majority voted in favor of the proposal includes a majority
of the ordinary shares held by non-controlling shareholders who do
not have a conflict of interest (referred to as a “personal
interest” under the Israeli Companies Law) in the approval of the
proposal that are voted at the meeting, excluding abstentions;
or
- the total number of ordinary shares held by non-controlling,
non-conflicted shareholders (as described in the previous
bullet-point) voted against approval of the proposal does not
exceed two percent (2%) of the aggregate voting rights in the
Company.
The presence (in person or by proxy) of any two or
more shareholders holding, in the aggregate, at least 25% of the
voting rights in the Company constitutes a quorum for purposes of
the Meeting. In the absence of the requisite quorum of shareholders
at the Meeting, the Meeting will be adjourned to the same day in
the next week, at the same time and place, unless otherwise
determined at the Meeting in accordance with the Company’s articles
of association. At such adjourned meeting the presence of at least
two shareholders in person or by proxy (regardless of the voting
power represented by their shares) will constitute a quorum.
Shareholders who are unable to attend the Meeting
in person will be requested to complete, date and sign their proxy
cards and return them promptly in the pre-addressed envelope that
will be provided, so as to be received not less than forty eight
(48) hours in advance of the Meeting, unless such deadline is
waived by the chairman of the Meeting. No postage will be required
if it is mailed in the United States to the Company’s United States
transfer agent, American Stock Transfer & Trust Company.
Shareholders who attend the Meeting in person may revoke their
proxies and vote their ordinary shares at the Meeting.
If your ordinary shares in the Company are held in
“street name” (meaning held through a bank, broker or other
nominee), you will be able to either direct the record holder of
your shares on how to vote your shares or obtain a legal proxy from
the record holder to enable you to participate in and to vote your
shares at the Meeting (or to appoint a proxy to do so).
Additional Information and Where to Find
It
In connection with the Meeting, the Company will
make available to its shareholders of record a proxy statement
describing the time and place, and other logistical information
related to the Meeting, and the proposal to be voted upon at the
Meeting, along with a proxy card enabling them to indicate their
vote on the proposal. The Company will also furnish copies of the
proxy statement and proxy card to the Securities and Exchange
Commission, or SEC, on a Report of Foreign Private Issuer on Form
6-K, which may be obtained for free from the SEC’s website at
www.sec.gov and will be available on the Company’s website
at www.enzymotec.com.
The full text of the proposed resolution for the
Meeting, together with the form of proxy card, may also be viewed
beginning on Monday, March 20, 2017, at the registered office of
the Company, Sagi 2000 Industrial Area, Migdal Ha’Emeq 2310001,
Israel, from Sunday to Thursday (excluding holidays), 10:00 a.m. to
5:00 p.m. (Israel time). The Company’s telephone number
at its registered office is +972-74-717-7177.
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty
lipid-based products and solutions. The Company develops,
manufactures and markets innovative bio-active lipid ingredients,
as well as final products, based on sophisticated processes and
technologies.
For more information, visit
www.enzymotec.com.
Company Contact
Enzymotec Ltd.
Oren Bryan
Chief Financial Officer
Phone: +972747177177
ir@enzymotec.com
Investor Relations Contact (U.S.)
The Ruth Group
Tram Bui / Lee Roth
Phone: 646-536-7035 / 7012
tbui@theruthgroup.com
lroth@theruthgroup.com
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024